Documented regulatory authorship and statistical synergy across high-complexity clinical indicationsβfrom oncology and neurodegenerative disorders to acute respiratory care and pediatric endocrinology.
Over 23 years of hands-on experience authoring protocols, CSRs, safety narratives, and submission dossiers for global trial programs.
Deep experience navigating complex solid tumor and hematologic malignancy protocols, handling multi-arm adaptive trials, immune-related response criteria (irRECIST), and intricate time-to-event statistical endpoints (Overall Survival, Progression-Free Survival], Duration of Response).
From First-in-Human dose escalation protocols to registrational Phase III global dossiers and real-world post-marketing observational registries.